🇺🇸 FDA

Intelligence · Clinical Pipeline

Nektar Therapeutics UK Pipeline

All ClinicalTrials.gov programs at Nektar Therapeutics UK — phase, modality, and trial IDs.

Programs
57

Quick answer

Nektar Therapeutics UK has 57 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Amikacin Inhalation Solution (BAY41-6551)

    Nektar Therapeutics UK Limited

    Pneumonia, Bacterial

    phase 3 small molecule completed

    1 trial

  2. Bempegaldesleukin

    Nektar Therapeutics UK Limited

    Metastatic Head and Neck Cancer

    phase 3 small molecule terminated

    1 trial

  3. Bempegaldesleukin

    Nektar Therapeutics UK Limited

    Melanoma

    phase 3 mab terminated

    1 trial

  4. Inhaled Human Insulin

    Nektar Therapeutics UK Limited

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  5. NKTR-102

    Nektar Therapeutics UK Limited

    Metastasis

    phase 3 small molecule completed

    1 trial

  6. NKTR-102

    Nektar Therapeutics UK Limited

    Locally Recurrent Breast Cancer

    phase 3 small molecule completed

    1 trial

  7. NKTR-181 BID tablets

    Nektar Therapeutics UK Limited

    Low Back Pain

    phase 3 small molecule completed

    2 trials

  8. NKTR-214

    Nektar Therapeutics UK Limited

    Melanoma

    phase 3 mab completed

    1 trial

  9. NKTR-255 at 1.5 µg/kg

    Nektar Therapeutics UK Limited

    Non-Hodgkin Lymphoma

    phase 3 small molecule terminated

    1 trial

  10. Nivolumab

    Nektar Therapeutics UK Limited

    Bladder Cancer

    phase 3 mab completed

    1 trial

  11. bempegaldesleukin

    Nektar Therapeutics UK Limited

    Renal Cell Carcinoma

    phase 3 mab terminated

    1 trial

  12. Amikacin (BAY41-6551)

    Nektar Therapeutics UK Limited

    Pneumonia

    phase 2 small molecule completed

    1 trial

  13. Amikacin inhalation solution (BAY41-6551)

    Nektar Therapeutics UK Limited

    Pneumonia

    phase 2 small molecule completed

    1 trial

  14. Avelumab

    Nektar Therapeutics UK Limited

    Locally Advanced or Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  15. Bempegaldesleukin

    Nektar Therapeutics UK Limited

    Urinary Bladder Neoplasm

    phase 2 mab completed

    1 trial

  16. Dose Escalation Doublet: Combination of NKTR-214 + nivolumab

    Nektar Therapeutics UK Limited

    Melanoma

    phase 2 small molecule completed

    1 trial

  17. Dronabinol MDI

    Nektar Therapeutics UK Limited

    Migraine With Aura

    phase 2 small molecule completed

    1 trial

  18. Etirinotecan pegol

    Nektar Therapeutics UK Limited

    Anaplastic Astrocytomas

    phase 2 small molecule completed

    1 trial

  19. LY3471851

    Nektar Therapeutics UK Limited

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    2 trials

  20. LY3471851

    Nektar Therapeutics UK Limited

    Colitis, Ulcerative

    phase 2 small molecule terminated

    1 trial

  21. NKTR-102

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  22. NKTR-102

    Nektar Therapeutics UK Limited

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  23. NKTR-102 100 mg/m2

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  24. NKTR-102 145 mg/m2

    Nektar Therapeutics UK Limited

    Malignant Solid Tumor

    phase 2 small molecule completed

    1 trial

  25. NKTR-102 q14d

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  26. NKTR-181

    Nektar Therapeutics UK Limited

    Osteoarthritis of the Knee

    phase 2 small molecule completed

    1 trial

  27. NKTR-214

    Nektar Therapeutics UK Limited

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  28. NKTR-214

    Nektar Therapeutics UK Limited

    Unspecified Adult Solid Tumor, Protocol Specific

    phase 2 small molecule completed

    1 trial

  29. NKTR-214

    Nektar Therapeutics UK Limited

    Non-Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  30. NKTR-255

    Nektar Therapeutics UK Limited

    Lung Cancer

    phase 2 small molecule active

    1 trial

  31. NKTR-255

    Nektar Therapeutics UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  32. NKTR-262

    Nektar Therapeutics UK Limited

    Melanoma

    phase 2 small molecule terminated

    1 trial

  33. NKTR-358, Placebo

    Nektar Therapeutics UK Limited

    Alopecia Areata

    phase 2 small molecule active

    1 trial

  34. NKTR-358, Sodium Chloride 0.9% solution

    Nektar Therapeutics UK Limited

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  35. Nivolumab

    Nektar Therapeutics UK Limited

    Ependymoma

    phase 2 mab terminated

    1 trial

  36. Pegylated Irinotecan

    Nektar Therapeutics UK Limited

    Stage IV Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule completed

    1 trial

  37. Pegylated Irinotecan

    Nektar Therapeutics UK Limited

    Recurrent Small Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  38. Rezpegaldesleukin

    Nektar Therapeutics UK Limited

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  39. Rezpegaldesleukin

    Nektar Therapeutics UK Limited

    Alopecia Areata

    phase 2 small molecule active

    1 trial

  40. VB10.NEO

    Nektar Therapeutics UK Limited

    Locally Advanced or Metastatic Solid Tumours

    phase 2 mab completed

    1 trial

  41. aerosolized vancomycin or gentamicin

    Nektar Therapeutics UK Limited

    Ventilator Associated Pneumonia

    phase 2 small molecule completed

    1 trial

  42. avelumab

    Nektar Therapeutics UK Limited

    Squamous Cell Carcinoma of the Head and Neck (SCCHN)

    phase 2 small molecule terminated

    1 trial

  43. placebo

    Nektar Therapeutics UK Limited

    Opioid Induced Constipation (OIC)

    phase 2 small molecule completed

    1 trial

  44. 145 mg/m2 NKTR 102

    Nektar Therapeutics UK Limited

    Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  45. Bempegaldesleukin

    Nektar Therapeutics UK Limited

    Covid-19

    phase 1 small molecule completed

    1 trial

  46. Bempegaldesleukin (NKTR-214)

    Nektar Therapeutics UK Limited

    Metastatic Melanoma

    phase 1 mab terminated

    1 trial

  47. C-TIL051

    Nektar Therapeutics UK Limited

    Metastatic Non Small Cell Lung Cancer

    phase 1 mab terminated

    1 trial

  48. Cyclophosphamide

    Nektar Therapeutics UK Limited

    Recurrent Diffuse Large B-Cell Lymphoma

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Nektar Therapeutics UK have?

57 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.